<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Molecular pathogenesis of cutaneous squamous cell carcinoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Molecular pathogenesis of cutaneous squamous cell carcinoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Molecular pathogenesis of cutaneous squamous cell carcinoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth Y Tsai, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            June K Robinson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Stern, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 06, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2690706216">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous squamous cell carcinoma (cSCC) is among the most common of human cancers, with an estimated 1,000,000 new cases annually in the United States alone. Cutaneous ultraviolet (UV) radiation exposure is among the environmental exposures most closely linked to cSCC. It is estimated that some 5 percent of primary cSCCs become locally advanced or metastatic, most often to lymph nodes. Despite being the second most common skin cancer (after basal cell carcinoma), the exact incidence of cSCC is unknown. cSCCs as well as basal cell carcinomas are not typically reported to cancer registries, making it difficult to assess the global public health burden and social costs associated with these cancers [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This topic will discuss the molecular pathogenesis of cSCC. The epidemiology, clinical presentation, diagnosis, staging, and management of cSCC are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5337.html" rel="external">
          "Cutaneous squamous cell carcinoma: Epidemiology and risk factors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/128194.html" rel="external">
          "Cutaneous squamous cell carcinoma: Primary and secondary prevention"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16225.html" rel="external">
          "Cutaneous squamous cell carcinoma (cSCC): Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5339.html" rel="external">
          "Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13713.html" rel="external">
          "Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H363569098">
         <span class="h1">
          MOLECULAR PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin carcinogenesis is a multistep process of progressive and accumulating genetic and epigenetic alterations in key signaling pathways that regulate cell survival, cell cycle, and genome maintenance. Although the precise sequence of events leading to the development of invasive cSCC has not been defined, an increasing number of genetic alterations have been identified in cSCC and precursor lesions [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1521588750">
         <span class="h2">
          Cell of origin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The keratinocyte is the cell of origin of cSCC. Histologically, typical cSCC manifests as a malignant, keratinizing, squamous proliferation, emanating from the epidermis. As such, these cells are highly susceptible to ultraviolet (UV) radiation-mediated deoxyribonucleic acid (DNA) damage, which is manifest in the typical site distribution for cSCC and frequent findings of concomitant dermatoheliosis and solar elastosis. Although the risk of cSCC can be linked to many exposures, including UV radiation, ionizing radiation, human papillomaviruses (HPVs), and chemicals (arsenic), it is not known whether the development of cSCC results from distinct sets of genes or pathways being affected. The primary limitation is that cSCC has not been profiled as extensively, and data on subtypes linked to specific exposures are extremely limited and often difficult to compare [
         <a href="#rid4">
          4-6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H938792495">
         <span class="h2">
          The mutational landscape and impact of ultraviolet radiation exposure
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mutational landscape of cSCC is dominated by a large number of mutations, overwhelmingly represented by cytidine-to-thymidine transitions associated with repair of ultraviolet B (UVB) radiation-mediated DNA damage [
         <a href="#rid7">
          7-14
         </a>
         ]. The majority of these mutations represent inactivation or alteration of function of tumor suppressor genes in the absence of widely prevalent, dominant, oncogenic drivers, in contrast to the genetic landscape of melanoma  (
         <a class="graphic graphic_table graphicRef138466" href="/z/d/graphic/138466.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid15">
          15
         </a>
         ]. Tumor mutational burdens of &gt;45 mutations per megabase have been estimated, on par with those previously described for cutaneous melanoma [
         <a href="#rid15">
          15
         </a>
         ] and basal cell carcinoma [
         <a href="#rid16">
          16-18
         </a>
         ].
        </p>
        <p>
         A UV-induced cSCC model in hairless mice replicated the spectrum of mutations and putative driver genes observed in human cSCC very closely, thus providing a preclinical model for prevention and treatment of cSCC [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         The role of ionizing radiation in modifying the risk of cSCC is less relevant than for basal cell carcinoma, and molecularly distinct causes or signatures of cSCC attributed to ionizing versus UV radiation have not been identified [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2818911703">
         <span class="h2">
          Key genes and pathways
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple genomic studies have contributed to the delineation of the mutational landscape of cSCC [
         <a href="#rid7">
          7-13
         </a>
         ]. The key genes and pathways involved in the cSCC carcinogenesis are summarized in the table  (
         <a class="graphic graphic_table graphicRef138466" href="/z/d/graphic/138466.html" rel="external">
          table 1
         </a>
         ). NOTCH and TP53 pathways are prominently affected, broadly abrogating normal squamous differentiation and classical tumor suppression pathways [
         <a href="#rid22">
          22-27
         </a>
         ].
        </p>
        <p>
         <em>
          TP53
         </em>
         mutations were among the first to be identified in human cSCC [
         <a href="#rid28">
          28
         </a>
         ]. So-called "p53-mutant clones" were also described in normal-appearing, sun-damaged skin [
         <a href="#rid29">
          29
         </a>
         ]. Because mutation of
         <em>
          TP53
         </em>
         often leads to stabilization of the protein, these clones are assumed to represent cells expressing mutated
         <em>
          TP53
         </em>
         . As a prototypical tumor suppressor gene altered in some 50 percent of all human cancers, these findings were among the first to link
         <em>
          TP53
         </em>
         mutation to human cancer and to specify a role for UV-induced mutagenesis in this process [
         <a href="#rid28">
          28,30-32
         </a>
         ].
        </p>
        <p>
         In experimental systems, the disruption of NOTCH signaling is well established to result in the establishment of tumors in skin. Even removal of NOTCH signaling in the dermis alone can cause multifocal cSCC in mice [
         <a href="#rid33">
          33
         </a>
         ]. Taken across published exome and targeted sequencing studies, the other most frequently mutated tumor suppressor genes (other than
         <em>
          TP53
         </em>
         and
         <em>
          NOTCH
         </em>
         family members) are
         <em>
          CDKN2A
         </em>
         , atypical cadherin
         <em>
          FAT
         </em>
         family members, and the histone methyltransferases
         <em>
          KMT2C
         </em>
         and
         <em>
          KMT2D
         </em>
         [
         <a href="#rid7">
          7-10,12,34
         </a>
         ]. Other potential tumor suppressors include
         <em>
          CASP8
         </em>
         ,
         <em>
          CREBBP
         </em>
         , and
         <em>
          CARD11
         </em>
         [
         <a href="#rid35">
          35
         </a>
         ]. Mutant
         <em>
          HRAS
         </em>
         was present in 20 percent of cSCCs in at least one series [
         <a href="#rid9">
          9
         </a>
         ]. Amplifications in
         <em>
          c-MYC
         </em>
         ,
         <em>
          CCND1
         </em>
         , and
         <em>
          EGFR
         </em>
         , as well as loss of
         <em>
          CKS1B
         </em>
         and
         <em>
          INPP5A
         </em>
         , have been reported in cSCC [
         <a href="#rid13">
          13,36-39
         </a>
         ].
        </p>
        <p>
         A 2021 meta-analysis of whole-exome or whole-genome sequencing studies was performed to nominate a set of mutations likely to drive the formation of cSCC [
         <a href="#rid13">
          13
         </a>
         ]. Using a relatively small set of publicly available data, a group of likely "driver" mutations was codified, identifying those most likely to directly contribute to pathogenesis and the tumor phenotype  (
         <a class="graphic graphic_figure graphicRef134901" href="/z/d/graphic/134901.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid13">
          13
         </a>
         ]. The results reiterated the key important drivers, such as inactivation of
         <em>
          TP53
         </em>
         ,
         <em>
          NOTCH1
         </em>
         ,
         <em>
          NOTCH2
         </em>
         , and
         <em>
          CDKN2A
         </em>
         , and also importantly highlighted potentially targetable mutations in
         <em>
          HRAS
         </em>
         and
         <em>
          PIK3CA
         </em>
         , suggesting potential avenues of future targeted therapies.
        </p>
        <p>
         Some of these candidate drivers are corroborated by forward genetic mouse models based upon transposon mutagenesis across the entire genome, which can be studied in the context of specific tumor development (including cSCC) to identify novel drivers [
         <a href="#rid40">
          40
         </a>
         ]. This type of cross-species analysis has the potential to quickly identify key drivers of biologic import.
        </p>
        <p>
         One such example is IKK-alpha (CHUK), an upstream regulator of nuclear factor kappa B (NF-kB) signaling identified in both the human meta-analysis [
         <a href="#rid13">
          13
         </a>
         ] and in the transposon mutagenesis model [
         <a href="#rid40">
          40
         </a>
         ]. Removal of CHUK function in the skin of mice results in profound differentiation defects and formation of cSCC [
         <a href="#rid41">
          41,42
         </a>
         ] and likely reflects a part of the spectrum of known roles of the NF-kB pathway in ectodermal dysplasias such as incontinentia pigmenti [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1299879771">
         <span class="h2">
          Additional key pathways
         </span>
         <span class="headingEndMark">
          —
         </span>
         Proteomic interrogation of key cancer pathways shows upregulation of extracellular signal-regulated kinase (ERK) and mammalian (mechanistic) target of rapamycin (mTOR) signaling across the progression sequence of cSCC development [
         <a href="#rid44">
          44,45
         </a>
         ]. Transcriptional profiling implicates transcription factors, such as E2F and ETS2, as well as WNT, beta-catenin, and ERK signaling [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         ERK signaling is a canonical cell signaling pathway. In normal cells, this pathway is required for linking growth factor signaling to cell proliferation. It is frequently co-opted and hyperactivated in cancer.
        </p>
        <p>
         The importance of the ERK pathway signaling is additionally manifest in two scenarios of drug-induced cSCC:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         cSCC/keratoacanthoma-like lesions were described in the initial clinical trials of the B-Raf proto-oncogene (BRAF) inhibitor
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         , in which approximately 22 percent of treated patients with melanoma developed cSCC/keratoacanthoma-like lesions [
         <a href="#rid46">
          46-48
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/2088.html" rel="external">
          "Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy", section on 'BRAF inhibitors'
         </a>
         ). Mechanistically, the development of cSCC/keratoacanthoma-like lesions has been attributed to both paradoxical ERK signaling in
         <em>
          BRAF
         </em>
         wild-type cells [
         <a href="#rid49">
          49,50
         </a>
         ], occurring most often in the context of oncogenic mutant
         <em>
          HRAS
         </em>
         [
         <a href="#rid51">
          51
         </a>
         ], and to the suppression of apoptosis, which occurs as a result of off-target suppression of c-Jun N-terminal kinase (JNK) signaling [
         <a href="#rid52">
          52
         </a>
         ]. Accordingly, the concomitant use of mitogen-activated protein kinase kinase (MEK) with BRAF inhibitors, which is now standard of care, suppresses the emergence of these lesions [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Long-term therapy of basal cell carcinoma with the Smoothened (SMO) inhibitor
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         has been associated with the evolution of treated tumors to a cSCC-like morphology that is associated with drug resistance and activation of ERK signaling [
         <a href="#rid54">
          54,55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies", section on 'Basal cell carcinoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Collectively, these data strongly implicate ERK signaling as an important pathway in the pathogenesis of cSCC. This has also been validated in a UV radiation-driven preclinical model in which MEK inhibition had potent therapeutic and chemopreventive effects [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H557981614">
         <span class="h2">
          Chemical carcinogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chemical carcinogenesis of cSCC has been studied with the classical two-stage chemical carcinogenesis model in mice, in which a mutagen (eg, DMBA) is combined with a promoter (eg, a phorbol ester or UV radiation) to drive cancer formation [
         <a href="#rid57">
          57
         </a>
         ]. The main advantage of this model is the ability to precisely temporally and molecularly dissect tumor initiation, progression, and metastasis. The molecular genetic analysis of tumor development in this model identified Hras
         <sup>
          Q61R
         </sup>
         as the primary oncogenic driver of tumors [
         <a href="#rid58">
          58
         </a>
         ] one year following the cloning of
         <em>
          HRAS
         </em>
         as the first human proto-oncogene [
         <a href="#rid59">
          59
         </a>
         ]. Tumors in this model also show
         <em>
          Trp53
         </em>
         mutations at high frequency [
         <a href="#rid60">
          60
         </a>
         ]. However, in model systems, choice of mutagen matters greatly.
        </p>
        <p class="headingAnchor" id="H3384652232">
         <span class="h2">
          The roles of human papillomavirus
         </span>
         <span class="headingEndMark">
          —
         </span>
         The relationship between human papillomavirus (HPV) and cSCC has long been an area of intense interest. High-risk alpha-papillomaviruses are well-established, obligate drivers of most cervical squamous cell carcinomas (SCCs) and a minority of head and neck SCCs.
        </p>
        <p>
         The predominant HPVs found in skin are beta-HPV species, which share the same viral oncoprotein activities as alpha-HPV. However,
         <em>
          TP53
         </em>
         is commonly mutated, raising the question of whether viral oncogenic activities commonly ascribed to inactivation of p53 and pRB family members are necessary in this context. Ribonucleic acid (RNA) sequencing data fail to reveal HPV transcripts in cSCC, suggesting that HPV is not required for tumor maintenance [
         <a href="#rid12">
          12,61
         </a>
         ]. There is evidence to suggest that beta-HPV may contribute to tumorigenesis by being critically important at early stages of tumor development but dispensable in later ones [
         <a href="#rid62">
          62,63
         </a>
         ].
        </p>
        <p>
         A study using a mouse model of murine papillomavirus skin infection suggested that, as a commensal, beta-HPV in human skin may contribute to inciting a CD8+ T cell-dependent immunity that protects
         <strong>
          against
         </strong>
         SCC development driven by chemical carcinogen or UV exposure [
         <a href="#rid64">
          64
         </a>
         ]. However, how this finding can be reconciled with data suggesting a role of beta-HPV in promoting tumorigenesis through a "hit and run" mechanism, whereby beta-HPV plays an early cocarcinogenic role (eg, by suppressing cell death responses to UV radiation), remains to be defined. The "hit and run" mechanism implies the sustained maintenance of malignancy after the loss of viral "presence" in cancer cells [
         <a href="#rid65">
          65
         </a>
         ]. This is mechanistically distinct from how alpha-HPV species cause anogenital and cervical SCC, in which viral genome integration and elaboration of viral oncoproteins is required for both tumor initiation and maintenance.
        </p>
        <p class="headingAnchor" id="H538245776">
         <span class="h2">
          The genomic relationship between cSCC and SCC at other sites
         </span>
         <span class="headingEndMark">
          —
         </span>
         The genomic data assembled for cutaneous squamous cell carcinoma (cSCC) show important similarities between cSCC and squamous cell carcinoma (SCC) arising in other anatomic sites. Stratified squamous epithelia are exposed to a multitude of environmental insults, including carcinogens such as alcohol and tobacco, and genomic data likely reflect common molecular consequences to diverse exposures.
        </p>
        <p>
         For example,
         <em>
          TP53
         </em>
         mutations occur at over 70 percent frequency across all extensively profiled SCCs, such as head and neck, lung, and esophageal SCC.
         <em>
          NOTCH
         </em>
         family genes are mutated in over 70 percent of cSCCs [
         <a href="#rid7">
          7,8,10
         </a>
         ], 20 percent of oral (mucosal) head and neck SCCs [
         <a href="#rid66">
          66-68
         </a>
         ], 13 percent of lung SCCs [
         <a href="#rid69">
          69
         </a>
         ], and 10 percent of esophageal SCCs [
         <a href="#rid70">
          70
         </a>
         ]. SOX2 amplification is a common lineage-specific driver of SCC [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         These findings show that SCCs from diverse sites share pathway alterations, reflected in global gene expression and in
         <em>
          TP53
         </em>
         ,
         <em>
          TP63
         </em>
         ,
         <em>
          NOTCH
         </em>
         family, and
         <em>
          SOX2
         </em>
         signaling (in particular delta-Np63 activation) [
         <a href="#rid72">
          72
         </a>
         ]. There are less published transcriptomic and proteomic data, although the correspondence across nonviral SCCs is quite high [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H783613488">
         <span class="h1">
          DRUGS AND INTERACTIONS WITH ULTRAVIOLET RADIATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         , an immunosuppressant occasionally used for inflammatory dermatoses, gives rise to a novel mutational signature, which likely results from a unique interaction with ultraviolet A (UVA) radiation [
         <a href="#rid73">
          73
         </a>
         ]. This signature has been shown to reduce the overall contribution of the classic ultraviolet (UV) signature in exome data from cSCC arising in patients exposed to long-term azathioprine therapy [
         <a href="#rid74">
          74
         </a>
         ]. It is unclear how much this modifies risk of cSCC development or disease progression. (See
         <a class="medical medical_review" href="/z/d/html/16332.html" rel="external">
          "Epidemiology and risk factors for skin cancer in solid organ transplant recipients", section on 'Role of specific immunosuppressants'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3010627642">
         <span class="h1">
          SPECIAL SUBSETS OF CUTANEOUS SQUAMOUS CELL CARCINOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two circumstances where cSCC has a distinctly different clinical behavior is in immunosuppressed patients and in genodermatoses that predispose to cSCC.
        </p>
        <p class="headingAnchor" id="H1082641575">
         <span class="h2">
          Immunosuppressed patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         As has been well established in clinical experience with solid organ transplant recipients, the risk of developing cSCC in the context of pharmacologic immunosuppression to maintain graft integrity is at least 100-fold higher than in the general population [
         <a href="#rid75">
          75
         </a>
         ]. In this population, cSCCs are also known to be more aggressive, recur more frequently, and are potentially fatal [
         <a href="#rid76">
          76-78
         </a>
         ].
        </p>
        <p>
         In solid organ transplant recipients, immune surveillance is globally suppressed by drug therapy directed at T cells to prevent rejection. Moreover, immunosuppressive drugs given to solid organ transplant recipients may also contribute to specific mutations leading to oncogenesis. A gene mutation signature seen in cSCC arising in patients on
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         has also been demonstrated [
         <a href="#rid74">
          74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16332.html" rel="external">
          "Epidemiology and risk factors for skin cancer in solid organ transplant recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16339.html" rel="external">
          "Prevention and management of skin cancer in solid organ transplant recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H399720622">
         <span class="h2">
          Recessive dystrophic epidermolysis bullosa
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating genodermatosis caused by loss of function of collagen VII, resulting in subepidermal blisters; chronic wounds; and aggressive, lethal cSCCs. (See
         <a class="medical medical_review" href="/z/d/html/15449.html" rel="external">
          "Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Dystrophic epidermolysis bullosa'
         </a>
         .)
        </p>
        <p>
         Mutational profiling of these tumors implicates different drivers of mutations. First, it appears that the ultraviolet (UV) signature is significantly less dominant. Instead, these tumors have a high apolipoprotein B messenger RNA (mRNA) editing enzyme, catalytic polypeptide-like (APOBEC) signature as well as decreased APOBEC3A/B expression, with approximately two-thirds of the mutations being attributed to this mutation driver [
         <a href="#rid79">
          79
         </a>
         ]. The APOBEC enzymes are cytidine deaminases, which can drive endogenous mutational processes independently from external, UV radiation-mediated mutagenesis. The accelerated pace of the APOBEC-driven mutational process in the context of the chronic inflammation of chronic wounds in patients with RDEB may explain the early onset of cSCC in these patients.
        </p>
        <p class="headingAnchor" id="H3079075637">
         <span class="h2">
          Xeroderma pigmentosum
         </span>
         <span class="headingEndMark">
          —
         </span>
         Xeroderma pigmentosum (XP) is a rare genodermatosis caused by mutations in any of eight genes involved in the recognition and repair of UV radiation-induced DNA damage in a pathway called nucleotide excision repair [
         <a href="#rid80">
          80
         </a>
         ]. This crucial mechanism of DNA repair is required for removal of mutagenic ultraviolet B (UVB) induced DNA photoproducts. Thus, affected individuals who have inherited these disease-associated alleles in autosomal recessive fashion are exquisitely photosensitive and at &gt;10,000-fold higher risk of developing skin cancers, including keratinocytic carcinomas and melanoma, compared with nonaffected individuals. (See
         <a class="medical medical_review" href="/z/d/html/15466.html" rel="external">
          "Xeroderma pigmentosum"
         </a>
         .)
        </p>
        <p>
         The mutational spectrum does not appear to be drastically different from that of sporadic, UV radiation-driven cSCC. However, the mutational burden in transcribed areas of the genomes is fivefold higher in cSCC in patients with XP as compared with cSCC not associated with XP and likely represents the mechanistic basis for the vastly increased susceptibility to skin cancer in childhood among these patients [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3334941921">
         <span class="h1">
          CHRONICALLY ULTRAVIOLET-DAMAGED SKIN AND PRENEOPLASTIC INTERMEDIATES
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronically ultraviolet-damaged skin
         </strong>
         – Through whole-exome sequencing [
         <a href="#rid12">
          12
         </a>
         ] and targeted sequencing [
         <a href="#rid82">
          82
         </a>
         ], it has been shown that chronically ultraviolet (UV) exposed skin has a mutational burden comparable with that of many human cancers [
         <a href="#rid83">
          83
         </a>
         ]. Nonlesional, UV-damaged skin contains clones of keratinocytes, potentially up to several mm
         <sup>
          2
         </sup>
         in size, bearing mutations known to be relevant in cSCC. In genomic terms, these areas are considered preneoplastic. At a very basic level, these observations suggest that a large mutation burden alone is insufficient to drive tumor formation and that additional constraints, perhaps structural and immunologic, play key roles in suppressing tumor formation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Actinic keratosis
         </strong>
         – The rate of progression of preneoplastic actinic keratoses (AKs) to cSCC is thought to be as high as 2.6 percent in four years [
         <a href="#rid84">
          84
         </a>
         ], though data regarding the natural history of AKs are likely imprecise. At the genomic level, many of the key mutated genes observed in cSCC and irradiated skin are also found in AK [
         <a href="#rid12">
          12,85
         </a>
         ], with no consistently identified transcriptional differences. Instead, the molecular profiles of most AKs are largely indistinguishable from those of well-differentiated invasive cSCC, suggesting that chemoprevention directed against mutagenized, sun-exposed skin may be effective in halting the development of cancer [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13712.html" rel="external">
          "Actinic keratosis: Epidemiology, clinical features, and diagnosis", section on 'Progression to skin cancer'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13712.html" rel="external">
          "Actinic keratosis: Epidemiology, clinical features, and diagnosis", section on 'Risk for skin cancer in other sites'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3944169690">
         <span class="h1">
          IMPLICATIONS FOR THERAPY AND PREVENTION
         </span>
        </p>
        <p class="headingAnchor" id="H429238308">
         <span class="h2">
          Therapy for advanced disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         One of the best established, though not universal, determinants of immunotherapy response is tumor mutation burden (TMB). This is expected to correlate positively with neoantigen load (NAL). Neoantigens are peptides produced by tumor tissue bearing mutations bound to major histocompatibility complex (MHC) class I molecules [
         <a href="#rid86">
          86
         </a>
         ]. For many cutaneous malignancies, the response to immunotherapy is likely related to the high TMB related to ultraviolet (UV) radiation-mediated mutagenesis [
         <a href="#rid87">
          87
         </a>
         ]. An exception is virally driven Merkel cell carcinoma, in which it is likely that very high-quality viral oncoprotein antigens drive responses to immunotherapy. (See
         <a class="medical medical_review" href="/z/d/html/7623.html" rel="external">
          "Pathogenesis, clinical features, and diagnosis of Merkel cell (neuroendocrine) carcinoma"
         </a>
         .)
        </p>
        <p>
         Systemic therapies for cSCC are dominated by the inhibition of the immune checkpoints cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1). Only anti-PD-1 therapy is approved by the US Food and Drug Administration for advanced and metastatic disease, with very promising trial results in the neoadjuvant setting for
         <a class="drug drug_general" data-topicid="119172" href="/z/d/drug information/119172.html" rel="external">
          cemiplimab
         </a>
         [
         <a href="#rid88">
          88
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies", section on 'Cutaneous squamous cell carcinoma'
         </a>
         .)
        </p>
        <p>
         Although not approved for the therapy of cSCC, epidermal growth factor receptor (EGFR) inhibition has long been employed to treat cSCC, based upon limited trial evidence. Two phase 2 trials demonstrated benefit of using
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         first line in unresectable squamous cell carcinoma (SCC) [
         <a href="#rid89">
          89
         </a>
         ] and
         <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">
          gefitinib
         </a>
         in the neoadjuvant setting, some in combination with surgery [
         <a href="#rid90">
          90
         </a>
         ]. However, this success with gefitinib was not replicated in incurable, recurrent, or metastatic cSCC [
         <a href="#rid91">
          91
         </a>
         ]. This experience highlights a lack of understanding of mechanism and biomarkers of response. Oncogenic
         <em>
          EGFR
         </em>
         mutations found in lung cancer are not frequently observed in cSCC, and responses to EGFR inhibitors are not linked to EGFR expression level, amplification, or activation [
         <a href="#rid89">
          89-92
         </a>
         ]. Clear relationships to the function of other members of the ErbB family have not been clearly established, indicating that there are still multiple opportunities to address important, unmet needs in cSCC.
        </p>
        <p class="headingAnchor" id="H2897621173">
         <span class="h2">
          Chemoprevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         While there has been tremendous progress in the development of novel approaches to skin cancer treatment, the management of field cancerization, especially in consideration of the high mutation burden of sun-exposed skin, remains largely uninformed by genomics data. While mitogen-activated protein kinase kinase (MEK) inhibition may be such a targeted approach, other targetable pathways, such as WNT, beta-catenin, and E2F/cell cycle pathways, may potentially be leveraged as well for prevention.
        </p>
        <p>
         Data suggest that epigenetic modulation through histone deacetylase (HDAC) inhibition may be useful as well [
         <a href="#rid93">
          93-95
         </a>
         ]. HDAC1 and HDAC2 are required for maintenance of proliferative capacity of basal keratinocytes; removal of their enzymatic activity promotes aberrant differentiation and apoptosis. In preclinical studies, chemical inhibition of HDAC activity exhibits antitumor activity and induces differentiation, suggesting that these approaches may be useful therapeutically [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3021422203">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/133179.html" rel="external">
          "Society guideline links: Cutaneous squamous cell carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1948200859">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cell of origin and mutational landscape of cutaneous squamous cell carcinoma
         </strong>
         – The keratinocyte is the cell of origin of cutaneous squamous cell carcinoma (cSCC). These cells are highly susceptible to ultraviolet (UV) radiation-mediated DNA damage and also to other exposures, including ionizing radiation, human papillomaviruses (HPVs), and chemicals. The mutational landscape of cSCC is dominated by a large number of mutations, overwhelmingly represented by cytidine-to-thymidine transitions associated with repair of ultraviolet B (UVB) radiation-mediated DNA damage. Key genes and pathways involved in cSCC carcinogenesis include
         <em>
          TP53
         </em>
         ,
         <em>
          NOTCH
         </em>
         ,
         <em>
          FAT1
         </em>
         , and
         <em>
          CDKN2A
         </em>
         (
         <a class="graphic graphic_table graphicRef138466" href="/z/d/graphic/138466.html" rel="external">
          table 1
         </a>
         ). The extracellular signal-regulated kinase (ERK) signaling appears to be an additional important pathway in the pathogenesis of cSCC. (See
         <a class="local">
          'Cell of origin'
         </a>
         above and
         <a class="local">
          'The mutational landscape and impact of ultraviolet radiation exposure'
         </a>
         above and
         <a class="local">
          'Key genes and pathways'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of human papillomavirus
         </strong>
         – The predominant human papillomaviruses (HPVs) found in skin are beta-HPV species, which share the same viral oncoprotein activities as alpha-HPV involved in the oncogenesis of most cervical cancers. HPV may promote tumorigenesis through a "hit and run" mechanism, whereby the virus plays an early cocarcinogenic role without viral genome integration in the tumor cell. (See
         <a class="local">
          'The roles of human papillomavirus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Implications for therapy and prevention
         </strong>
         – The therapeutic implications of the molecular pathogenic mechanisms can lead to targeted approaches based on potential mutational, epigenetic, and transcriptional drivers. (See
         <a class="local">
          'Implications for therapy and prevention'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies", section on 'Eligible for immunotherapy'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 2013; 68:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harwood CA, Proby CM, Inman GJ, Leigh IM. The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma. Acta Derm Venereol 2016; 96:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Nardo L, Pellegrini C, Di Stefani A, et al. Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. J Eur Acad Dermatol Venereol 2020; 34:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu CH, Yang SA, Wang JY, et al. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br J Cancer 1999; 80:1080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rollison DE, Amorrortu RP, Zhao Y, et al. Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas. Cancer Res 2021; 81:4628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Aldabagh B, Yu J, Arron ST. Role of human papillomavirus in cutaneous squamous cell carcinoma: a meta-analysis. J Am Acad Dermatol 2014; 70:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           South AP, Purdie KJ, Watt SA, et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol 2014; 134:2630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang NJ, Sanborn Z, Arnett KL, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A 2011; 108:17761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pickering CR, Zhou JH, Lee JJ, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 2014; 20:6582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li YY, Hanna GJ, Laga AC, et al. Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res 2015; 21:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Rohil RN, Tarasen AJ, Carlson JA, et al. Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. Cancer 2016; 122:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chitsazzadeh V, Coarfa C, Drummond JA, et al. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun 2016; 7:12601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang D, Shain AH. The landscape of driver mutations in cutaneous squamous cell carcinoma. NPJ Genom Med 2021; 6:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brash DE. UV signature mutations. Photochem Photobiol 2015; 91:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 2015; 161:1681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonilla X, Parmentier L, King B, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet 2016; 48:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharpe HJ, Pau G, Dijkgraaf GJ, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell 2015; 27:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol 2014; 134:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knatko EV, Praslicka B, Higgins M, et al. Whole-Exome Sequencing Validates a Preclinical Mouse Model for the Prevention and Treatment of Cutaneous Squamous Cell Carcinoma. Cancer Prev Res (Phila) 2017; 10:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azizova TV, Bannikova MV, Grigoryeva ES, Rybkina VL. Risk of skin cancer by histological type in a cohort of workers chronically exposed to ionizing radiation. Radiat Environ Biophys 2021; 60:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshinaga S, Hauptmann M, Sigurdson AJ, et al. Nonmelanoma skin cancer in relation to ionizing radiation exposure among U.S. radiologic technologists. Int J Cancer 2005; 115:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dotto GP. Notch tumor suppressor function. Oncogene 2008; 27:5115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dotto GP. Crosstalk of Notch with p53 and p63 in cancer growth control. Nat Rev Cancer 2009; 9:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lefort K, Dotto GP. Notch signaling in the integrated control of keratinocyte growth/differentiation and tumor suppression. Semin Cancer Biol 2004; 14:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mammucari C, Tommasi di Vignano A, Sharov AA, et al. Integration of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control. Dev Cell 2005; 8:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolas M, Wolfer A, Raj K, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003; 33:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rangarajan A, Talora C, Okuyama R, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 2001; 20:3427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A 1991; 88:10124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jonason AS, Kunala S, Price GJ, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A 1996; 93:14025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierceall WE, Mukhopadhyay T, Goldberg LH, Ananthaswamy HN. Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas. Mol Carcinog 1991; 4:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiss M, Brash DE, Muñoz-Antonia T, et al. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncol Res 1992; 4:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu B, Castillo E, Harewood L, et al. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell 2012; 149:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CS, Bhaduri A, Mah A, et al. Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma. Nat Genet 2014; 46:1060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watt SA, Purdie KJ, den Breems NY, et al. Novel CARD11 Mutations in Human Cutaneous Squamous Cell Carcinoma Lead to Aberrant NF-κB Regulation. Am J Pathol 2015; 185:2354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salgado R, Toll A, Alameda F, et al. CKS1B amplification is a frequent event in cutaneous squamous cell carcinoma with aggressive clinical behaviour. Genes Chromosomes Cancer 2010; 49:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sekulic A, Kim SY, Hostetter G, et al. Loss of inositol polyphosphate 5-phosphatase is an early event in development of cutaneous squamous cell carcinoma. Cancer Prev Res (Phila) 2010; 3:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toll A, Salgado R, Yébenes M, et al. MYC gene numerical aberrations in actinic keratosis and cutaneous squamous cell carcinoma. Br J Dermatol 2009; 161:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toll A, Salgado R, Yébenes M, et al. Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. Exp Dermatol 2010; 19:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aiderus A, Newberg JY, Guzman-Rojas L, et al. Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression. PLoS Genet 2021; 17:e1009094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sil AK, Maeda S, Sano Y, et al. IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature 2004; 428:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xia X, Park E, Fischer SM, Hu Y. Mouse Genetic Models Reveal Surprising Functions of IkB Kinase Alpha in Skin Development and Skin Carcinogenesis. Cancers (Basel) 2013; 5:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maubach G, Schmädicke AC, Naumann M. NEMO Links Nuclear Factor-κB to Human Diseases. Trends Mol Med 2017; 23:1138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einspahr JG, Calvert V, Alberts DS, et al. Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma. Cancer Prev Res (Phila) 2012; 5:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einspahr JG, Bowden GT, Alberts DS, et al. Cross-validation of murine UV signal transduction pathways in human skin. Photochem Photobiol 2008; 84:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vin H, Ojeda SS, Ching G, et al. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife 2013; 2:e00969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ransohoff KJ, Tang JY, Sarin KY. Squamous Change in Basal-Cell Carcinoma with Drug Resistance. N Engl J Med 2015; 373:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao X, Ponomaryov T, Ornell KJ, et al. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors. Cancer Res 2015; 75:3623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adelmann CH, Truong KA, Liang RJ, et al. MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma. J Invest Dermatol 2016; 136:1920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abel EL, Angel JM, Kiguchi K, DiGiovanni J. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc 2009; 4:1350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balmain A, Pragnell IB. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 1983; 303:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982; 297:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nassar D, Latil M, Boeckx B, et al. Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nat Med 2015; 21:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arron ST, Ruby JG, Dybbro E, et al. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol 2011; 131:1745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasche D, Stephan S, Braspenning-Wesch I, et al. The interplay of UV and cutaneous papillomavirus infection in skin cancer development. PLoS Pathog 2017; 13:e1006723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambert PF, Münger K, Rösl F, et al. Beta human papillomaviruses and skin cancer. Nature 2020; 588:E20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strickley JD, Messerschmidt JL, Awad ME, et al. Immunity to commensal papillomaviruses protects against skin cancer. Nature 2019; 575:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreira DA, Tayyar Y, Idris A, McMillan NAJ. A "hit-and-run" affair - A possible link for cancer progression in virally driven cancers. Biochim Biophys Acta Rev Cancer 2021; 1875:188476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin DC, Hao JJ, Nagata Y, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 2014; 46:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell JD, Yau C, Bowlby R, et al. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep 2018; 23:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309:1871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inman GJ, Wang J, Nagano A, et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Nat Commun 2018; 9:3667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rangwala S, Tsai KY. Roles of the immune system in skin cancer. Br J Dermatol 2011; 165:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zwald F, Leitenberger J, Zeitouni N, et al. Recommendations for Solid Organ Transplantation for Transplant Candidates With a Pretransplant Diagnosis of Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma and Melanoma: A Consensus Opinion From the International Transplant Skin Cancer Collaborative (ITSCC). Am J Transplant 2016; 16:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovach BT, Stasko T. Skin cancer after transplantation. Transplant Rev (Orlando) 2009; 23:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez JC, Otley CC, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003; 139:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho RJ, Alexandrov LB, den Breems NY, et al. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Sci Transl Med 2018; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraemer KH, DiGiovanna JJ. Forty years of research on xeroderma pigmentosum at the US National Institutes of Health. Photochem Photobiol 2015; 91:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng CL, Wang NJ, Chung J, et al. Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes. Cell Rep 2014; 9:1228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martincorena I, Roshan A, Gerstung M, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015; 348:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115:2523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albibas AA, Rose-Zerilli MJJ, Lai C, et al. Subclonal Evolution of Cancer-Related Gene Mutations in p53 Immunopositive Patches in Human Skin. J Invest Dermatol 2018; 138:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zou XL, Li XB, Ke H, et al. Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer. Front Immunol 2021; 12:689076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 2019; 30:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrarotto R, Amit M, Nagarajan P, et al. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 2021; 27:4557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29:3419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis CM, Glisson BS, Feng L, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 2012; 18:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           William WN Jr, Feng L, Ferrarotto R, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol 2017; 77:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bejar C, Maubec E. Therapy of advanced squamous cell carcinoma of the skin. Curr Treat Options Oncol 2014; 15:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kilgour JM, Shah A, Urman NM, et al. Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma. Clin Cancer Res 2021; 27:4717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu X, Leboeuf M, Liu F, et al. HDAC1/2 Control Proliferation and Survival in Adult Epidermis and Pre‒Basal Cell Carcinoma through p16 and p53. J Invest Dermatol 2022; 142:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeBoeuf M, Terrell A, Trivedi S, et al. Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells. Dev Cell 2010; 19:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakiuchi A, Kakuki T, Ohwada K, et al. HDAC inhibitors suppress the proliferation, migration and invasiveness of human head and neck squamous cell carcinoma cells via p63‑mediated tight junction molecules and p21‑mediated growth arrest. Oncol Rep 2021; 45.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 128445 Version 2.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23375456" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26084328" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31747091" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10362120" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34266893" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24629358" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Role of human papillomavirus in cutaneous squamous cell carcinoma: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24662767" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22006338" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25303977" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Mutational landscape of aggressive cutaneous squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25589618" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Genomic analysis of metastatic cutaneous squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26479420" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27574101" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34272401" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The landscape of driver mutations in cutaneous squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25354245" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : UV signature mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26091043" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Genomic Classification of Cutaneous Melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26950094" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25759019" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23774526" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Mutational landscape of basal cell carcinomas by whole-exome sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27923803" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Whole-Exome Sequencing Validates a Preclinical Mouse Model for the Prevention and Treatment of Cutaneous Squamous Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33389049" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Risk of skin cancer by histological type in a cohort of workers chronically exposed to ionizing radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15704092" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Nonmelanoma skin cancer in relation to ionizing radiation exposure among U.S. radiologic technologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18758480" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Notch tumor suppressor function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19609265" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Crosstalk of Notch with p53 and p63 in cancer growth control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15288263" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Notch signaling in the integrated control of keratinocyte growth/differentiation and tumor suppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15866158" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Integration of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12590261" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Notch1 functions as a tumor suppressor in mouse skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11432830" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1946433" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8943054" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Frequent clones of p53-mutated keratinocytes in normal human skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1793482" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1486218" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7997263" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Sunburn and p53 in the onset of skin cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22682244" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25194279" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26212909" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Novel CARD11 Mutations in Human Cutaneous Squamous Cell Carcinoma Lead to Aberrant NF-κB Regulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20737481" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : CKS1B amplification is a frequent event in cutaneous squamous cell carcinoma with aggressive clinical behaviour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20876729" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Loss of inositol polyphosphate 5-phosphatase is an early event in development of cutaneous squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19673870" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : MYC gene numerical aberrations in actinic keratosis and cutaneous squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20156290" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34398873" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15071597" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24216703" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mouse Genetic Models Reveal Surprising Functions of IkB Kinase Alpha in Skin Development and Skin Carcinogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29128367" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : NEMO Links Nuclear Factor-κB to Human Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22389437" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18248498" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Cross-validation of murine UV signal transduction pathways in human skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21639808" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20818844" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Inhibition of mutated, activated BRAF in metastatic melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22356324" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20130576" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20179705" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22256804" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24192036" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23020132" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26352826" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Squamous Change in Basal-Cell Carcinoma with Drug Resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26130651" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27293029" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19713956" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6843661" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6283357" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26168291" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21490616" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29190285" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The interplay of UV and cutaneous papillomavirus infection in skin cancer development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33328661" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Beta human papillomaviruses and skin cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31666702" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Immunity to commensal papillomaviruses protects against skin cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33186643" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A "hit-and-run" affair - A possible link for cancer progression in virally driven cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21798893" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The mutational landscape of head and neck squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21798897" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25631445" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Comprehensive genomic characterization of head and neck squamous cell carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22960745" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Comprehensive genomic characterization of squamous cell lung cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24686850" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Genomic and molecular characterization of esophageal squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19801978" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29617660" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16166520" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Azathioprine and UVA light generate mutagenic oxidative DNA damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30202019" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21729024" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Roles of the immune system in skin cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26820755" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Recommendations for Solid Organ Transplantation for Transplant Candidates With a Pretransplant Diagnosis of Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma and Melanoma: A Consensus Opinion From the International Transplant Skin Cancer Collaborative (ITSCC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19345080" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Skin cancer after transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12622621" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30135250" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25220021" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Forty years of research on xeroderma pigmentosum at the US National Institutes of Health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25456125" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25999502" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23945592" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Signatures of mutational processes in human cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19382202" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28844940" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Subclonal Evolution of Cancer-Related Gene Mutations in p53 Immunopositive Patches in Human Skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34992591" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30395155" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34187851" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21810686" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22261807" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28964539" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24643778" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Therapy of advanced squamous cell carcinoma of the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34362809" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34284046" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : HDAC1/2 Control Proliferation and Survival in Adult Epidermis and Pre‒Basal Cell Carcinoma through p16 and p53.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21093383" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33649777" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : HDAC inhibitors suppress the proliferation, migration and invasiveness of human head and neck squamous cell carcinoma cells via p63‑mediated tight junction molecules and p21‑mediated growth arrest.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
